Practice Administration

Strategic Planning by Oncology Practices Can Provide a Roadmap to a Thriving Future

Elaine Estes

July 2018, Vol 8, No 7 - Practice Administration, Strategic Planning

Strategic planning for oncology practices is more important today than ever before, with the oncology landscape rapidly evolving, driven by complex issues not encountered previously. For example, the emergence of value-based care has added new layers of complexity to cancer care, because clinical changes associated with team-based care and documentation and data-­tracking requirements are significant. Practices today are also tasked with finding ways to expand patient access to ancillary support services that improve satisfaction and outcomes, while also keeping costs down. [ Read More ]

FDA Implements New Steps to Encourage Generic Drug Competition, Expand Patients’ Access to Inexpensive Medicines

Eileen Koutnik-Fotopoulos

April 2018, Vol 8, No 4 - Health Policy

In a January 3, 2018, statement from FDA Commissioner Scott Gottlieb, MD, the FDA announced new steps to promote generic drug competition as a way to expand potential access to inexpensive medicines, which would be especially helpful for patients with cancer. These new steps are a part of the FDA’s ongoing implementation of the Drug Competition Action Plan. [ Read More ]

Managing Self-Pay Accounts Receivable in Oncology

Matt Terry, MBA, BSRT

September 2017, Vol 7, No 9 - Billing/Accounts Receivable

Self-pay accounts receivable in healthcare includes true self-pay (ie, patients with no health insurance) and the patient responsibility after insurance. In the past, health insurance plan benefits covered much more of the patient’s bill, up to 90% or more; however, in the past few years, high-deductible health plans have become more common and more attractive for plan members because of lower monthly premiums. Thus, the patient responsibility after insurance has shifted from 10% of the collectible accounts receivable to upwards of 30%. [ Read More ]

Drug Pricing Under the Trump Administration

Meg Barbor, MPH

July 2017, Vol 7, No 7 - Health Policy

Washington, DC—A change in leadership brings with it healthcare reform and potential changes in drug pricing in the United States, said Jessica Turgon, MBA, Principal, ECG Management Consultants, Washington, DC, at the 2017 Association of Community Cancer Centers meeting. Ms Turgon discussed what this transition of power means for cancer centers, and what oncology providers can realistically expect under the Trump administration. [ Read More ]